GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Capex-to-Operating-Cash-Flow

Vicapsys Life Sciences (Vicapsys Life Sciences) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Vicapsys Life Sciences's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.11 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Vicapsys Life Sciences Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Capex-to-Operating-Cash-Flow Chart

Vicapsys Life Sciences Annual Data
Trend Dec08 Dec09 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Vicapsys Life Sciences Quarterly Data
Jun10 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow falls into.



Vicapsys Life Sciences Capex-to-Operating-Cash-Flow Calculation

Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.238
=N/A

Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.107
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicapsys Life Sciences  (OTCPK:VICP) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Vicapsys Life Sciences Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
Moore Bobby M Jr 10 percent owner 4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen 10 percent owner 9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski director 1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping 10 percent owner 2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees director C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser director 641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier director 1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon director, 10 percent owner 8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus